Background
Methods
Patients
Statistical analysis
Results
Variables | |
---|---|
Total number | 37 (100 %) |
Sex | |
Male | 18 (48.6 %) |
Female | 19 (51.4 %) |
Age, years | 62.57 ± 8.22 |
T stage | |
T1 | 14 (37.8 %) |
T2 | 8 (21.6 %) |
T3 | 14 (37.8 %) |
T4 | 1 (2.7 %) |
N stage | |
N0 | 31 (83.8 %) |
N1 | 6 (16.2 %) |
Overall stage | |
IA | 14 (37.8 %) |
IB | 6 (16.2 %) |
IIA | 11 (29.7 %) |
IIB | 5 (13.5 %) |
III | 1 (2.7 %) |
Tumor size (cm) | 2.58 ± 1.49 |
CA19-9 (U/ml) | 459.54 ± 1727.30 |
CEA (ng/ml) | 4.03 ± 5.65 |
Lymphovascular invasion | |
No | 31 (83.8 %) |
Yes | 6 (16.2 %) |
Perineural invasion | |
No | 30 (81.1 %) |
Yes | 7 (18.9 %) |
Differentiation | |
Well/Moderately | 31 (83.8 %) |
Poorly | 6 (16.2 %) |
Adjuvant therapy | |
No | 20 (54.0 %) |
Yes | 17 (46.0 %) |
Variables | N | 5 years survival rate | Overall survival | 5 years survival rate | Disease-free survival | ||
---|---|---|---|---|---|---|---|
Hazard ratio | P value | Hazard ratio | P value | ||||
Sex | |||||||
Male | 18 | 87.2 | 2.33 (0.45–12.05) | 0.311 | 77.8 | 1.07 (0.28–3.99) | 0.919 |
Female | 19 | 68.0 | 73.7 | ||||
Age, years | |||||||
< 60 | 14 | 80.0 | 1.79 (0.34–9.21) | 0.489 | 78.6 | 1.27 (0.32–5.09) | 0.733 |
≥ 60 | 23 | 75.9 | 73.9 | ||||
Subtype | |||||||
Intestinal | 17 | 93.3 | 8.45 (0.99–71.61) | 0.051 | 94.1 | 8.34 (1.04–66.88) | 0.046 |
Pancreaticobiliary | 20 | 60.5 | 60.0 | ||||
CK7 +/CK20 - | |||||||
No | 19 | 93.3 | 9.74 (1.16–81.89) | 0.036 | 89.5 | 4.31 (0.89–20.77) | 0.069 |
Yes | 18 | 57.5 | 61.1 | ||||
CDX2 | |||||||
No | 20 | 75.2 | 1.26 (0.28–5.68) | 0.764 | 75.0 | 1.02 (0.28–3.81) | 0.972 |
Yes | 16 | 79.3 | 75.0 | ||||
T stage | |||||||
T1, T2 | 22 | 95.2 | 13.94 (1.66–117.03) | 0.015 | 95.5 | 14.81 (1.85–118.92) | 0.011 |
T3, T4 | 15 | 45.4 | 46.7 | ||||
Lymph node metastasis | |||||||
No | 31 | 88.4 | 6.00 (1.30–27.58) | 0.021 | 83.9 | 5.69 (1.52–21.30) | 0.010 |
Yes | 6 | 33.3 | 33.3 | ||||
Lymphovascular invasion | |||||||
No | 31 | 85.1 | 5.89 (1.27–27.38) | 0.024 | 83.9 | 6.06 (1.58–23.28) | 0.009 |
Yes | 6 | 31.3 | 33.3 | ||||
Perineural invasion | |||||||
No | 30 | 84.0 | 4.83 (1.07–21.87) | 0.041 | 83.3 | 4.88 (1.29–18.40) | 0.019 |
Yes | 7 | 47.6 | 42.9 | ||||
Size | |||||||
< 2 cm | 14 | 83.1 | 1.92 (0.37–9.94) | 0.436 | 85.7 | 2.34 (0.49–11.25) | 0.290 |
≥ 2 cm | 23 | 73.8 | 69.6 | ||||
Differentiation | |||||||
Well/mod | 31 | 86.0 | 8.18 (1.57–42.67) | 0.013 | 87.1 | 12.29 (3.06–48.31) | <0.001 |
Poorly | 6 | 0 | 16.7 | ||||
Stage | |||||||
I and IIA | 31 | 88.4 | 6.00 (1.30–27.58) | 0.021 | 83.9 | 5.69 (1.52–21.30) | 0.010 |
IIB and III | 6 | 33.3 | 33.3 | ||||
Ca19-9 (U/ml) | |||||||
< 37 | 12 | 70.0 | 0.66 (0.13–3.28) | 0.611 | 66.7 | 0.40 (0.09–1.81) | 0.236 |
≥ 37 | 20 | 84.0 | 85.0 | ||||
CEA (ng/ml) | |||||||
< 5 | 27 | 83.2 | 1.28 (0.14–11.54) | 0.826 | 81.5 | 1.37 (0.16–11.74) | 0.774 |
≥ 5 | 4 | 75.0 | 75.0 | ||||
Pancreatic fistula | |||||||
No | 21 | 77.2 | 0.88 (0.20–3.95) | 0.872 | 71.4 | 0.59 (0.15–2.35) | 0.453 |
Yes | 16 | 77.9 | 81.3 | ||||
Adjuvant therapy | |||||||
No | 20 | 90.0 | 3.67 (0.70–19.02) | 0.122 | 90.0 | 5.11 (1.06–24.68) | 0.042 |
Yes | 17 | 58.2 | 58.8 |
Variables | Hazard ratio | P value |
---|---|---|
CK7+/CK20- | ||
No | Ref. | 0.046 |
Yes | 8.96 (1.04–77.38) | |
T stage | ||
T1, T2 | Ref. | 0.019 |
T3, T4 | 12.98 (1.52–110.78) | |
Lymph node metastasis | ||
No | Ref. | 0.276 |
Yes | 2.45 (0.49–12.33) | |
Lymphovascular invasion | ||
No | Ref. | 0.678 |
Yes | 0.67 (0.10–4.55) | |
Differentiation | ||
Well/mod | Ref. | 0.955 |
poorly | 1.05 (0.17–6.59) |
Variables | Hazard ratio | P value |
---|---|---|
Subtype | ||
Intestinal | Ref. | 0.664 |
Pancreaticobiliary | 1.72 (0.15–19.54) | |
T stage | ||
T1, T2 | Ref. | 0.063 |
T3, T4 | 8.21 (0.89–75.54) | |
Lymph node metastasis | ||
No | Ref. | 0.091 |
Yes | 3.35 (0.82–13.63) | |
Lymphovascular invasion | ||
No | Ref. | 0.447 |
Yes | 1.97 (0.34–11.39) | |
Differentiation | ||
Well/mod | Ref. | 0.031 |
poorly | 4.95 (1.16–21.18) |